製品番号: HY-122272

Paroxetine

(別名: BRL29060)

19 Cited Publications

カスタマーレビュー

Based on 19 publication(s) in Google Scholar

Paroxetine (BRL29060) is an orally active and selective serotonin reuptake inhibitor (SSRI) and apoptosis inducer with blood-brain barrier permeability. Paroxetine inhibits nitric oxide synthase and CYP2D6, induces desensitization of 5-HT1A/1B/1D autoreceptors, downregulates 5-HT2 receptors, and promotes the production of inflammatory cytokines. Paroxetine is a weak norepinephrine (NE) uptake inhibitor and possesses antitumor activity. Paroxetine is widely used in research concerning depression, obsessive-compulsive disorder, panic disorder, social phobia, generalized anxiety disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, hot flashes, and related conditions.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.66%
CAS 番号: 61869-08-7
分子式: C₁₉H₂₀FNO₃
分子量:329.37

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Paroxetine 構造式

CAS 番号: 61869-08-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
化学情報
Publications (19)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

CYP2D6

5-HT₂ Receptor

Cytochrome P450 アイソフォーム固有の製品をすべて表示 :

5-HT Receptor アイソフォーム固有の製品をすべて表示 :

NO Synthase アイソフォーム固有の製品をすべて表示 :

Estrogen Receptor/ERR アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
BTI-TN-5B1-4	IC₅₀	1.38 μM Compound: Paroxetine	Inhibition of full length C-terminal hexahistidine tagged GRK2 (unknown origin) S670A mutant expressed in High Five cells using Bac to Bac insect cell expression system using tubulin as substrate by SDS-PAGE method Inhibition of full length C-terminal hexahistidine tagged GRK2 (unknown origin) S670A mutant expressed in High Five cells using Bac to Bac insect cell expression system using tubulin as substrate by SDS-PAGE method	[PMID: 27050625]
CHO	IC₅₀	0.56 nM Compound: Paroxetine	Inhibition of human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake preincubated for 10 mins followed by [3H]serotonin addition measured after 20 mins by liquid scintillation counting method Inhibition of human SERT expressed in CHO cell membranes assessed as reduction in [3H]serotonin uptake preincubated for 10 mins followed by [3H]serotonin addition measured after 20 mins by liquid scintillation counting method	[PMID: 27865645]
CHO	IC₅₀	3.9 μM Compound: paroxetine	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	[PMID: 23812503]
HEK293	IC₅₀	0.2 nM Compound: paroxetine	Displacement of [125I]RTI-55 from human recombinant SERT expressed in HEK293 cells after 1 hr by scintillation counting analysis Displacement of [125I]RTI-55 from human recombinant SERT expressed in HEK293 cells after 1 hr by scintillation counting analysis	[PMID: 23477943]
JAR	IC₅₀	2 nM Compound: 2	Inhibition of serotonin uptake at human SERT expressed in JAR cells Inhibition of serotonin uptake at human SERT expressed in JAR cells	[PMID: 18771916]
MDCK	IC₅₀	100 nM Compound: 2	Inhibition of norepinephrine uptake at human NET expressed in MDCK cells Inhibition of norepinephrine uptake at human NET expressed in MDCK cells	[PMID: 18771916]
U-373MG ATCC	IC₅₀	900 nM Compound: paroxetine	Displacement of [125I]substance P from human recombinant NK1 receptor expressed in human U373 cells after 1 hr by scintillation counting analysis Displacement of [125I]substance P from human recombinant NK1 receptor expressed in human U373 cells after 1 hr by scintillation counting analysis	[PMID: 23477943]
Vero C1008	IC₅₀	7.45 μM Compound: Paroxetine	Antiviral activity against Ebolavirus infected in african green monkey Vero E6 cells assessed as reduction in virus entry after 48 hrs by by Celltiter-Glo luminescent assay Antiviral activity against Ebolavirus infected in african green monkey Vero E6 cells assessed as reduction in virus entry after 48 hrs by by Celltiter-Glo luminescent assay	[PMID: 29272110]

体外実験

Paroxetine potently and selectively inhibits serotonin reuptake in rat brain synaptosomes, with a K_i of 1.1 nmol/L, and shows much weaker activity against norepinephrine and dopamine reuptake^[1].
Paroxetine has no significant affinity for most tested neurotransmitter receptors in rat brain tissue, only showing weak binding to muscarinic cholinergic receptors with a K_i of 89 nmol/L^[1].
Paroxetine (76 nM) exhibits high affinity for the muscarinic M1 receptor, resulting in greater anticholinergic effects than other SSRIs^[2].
Paroxetine exhibits estrogenic activity in an in vitro assay that identifies chemicals disrupting aromatase and estrogen balance in humans, which may promote estrogen-sensitive breast tumor growth^[2].
Paroxetine (10-20 μM; 6-24 h) differentially modulates LPS-induced cytokine production in Raw264.7 mouse macrophages, potently inhibiting IL-6 production and enhancing TNFα production at 10 μM and 20 μM concentrations after 6 and 24 hours of incubation^[3].
Paroxetine (10-20 μM; 6-24 h) differentially modulates LPS-induced cytokine production in thioglycollate-elicited primary mouse peritoneal macrophages, potently inhibiting IL-6 production and enhancing TNFα production at 10 μM and 20 μM concentrations after 6 and 24 hours of incubation^[3].
Paroxetine (20 μM; 24 h) inhibits LPS-induced IL-6 production independent of 5-HT2/5-HT7 receptors and enhances LPS-induced TNFα production via 5-HT2/5-HT7 receptors in Raw264.7 mouse macrophages after 24 hours of incubation^[3].
Paroxetine (20 μM) modulates LPS-induced IL-6 and TNFα production in Raw264.7 mouse macrophages independently of GRK2, as its inhibitory effect on IL-6 and enhancing effect on TNFα are retained in GRK2-knockdown cells^[3].
Paroxetine (10-30 μM, 72 h) reduces the viability of MCF-7 cells in a time- and dose-dependent manner^[4].
Paroxetine (10-30 μM, 1-12 h) induces mitochondrial-mediated apoptosis in MCF-7, increasing ROS generation^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA Assay^[3]

Cell Line:

Raw264.7 mouse macrophages
Concentration:

10 μM; 20 μM
Incubation Time:

6 h; 24 h
Result:

Reduced LPS-induced IL-6 production to ~75% of LPS-only levels at 6 hours with 10 μM.
Reduced LPS-induced IL-6 production to ~50% of LPS-only levels at 6 hours with 20 μM.
Reduced LPS-induced IL-6 production to ~80% of LPS-only levels at 24 hours with 10 μM.
Reduced LPS-induced IL-6 production to ~60% of LPS-only levels at 24 hours with 20 μM.
Increased LPS-induced TNFα production to ~155% of LPS-only levels at 6 hours with 10 μM.
Increased LPS-induced TNFα production to ~195% of LPS-only levels at 6 hours with 20 μM.
Increased LPS-induced TNFα production to ~120% of LPS-only levels at 24 hours with 10 μM.
Increased LPS-induced TNFα production to ~145% of LPS-only levels at 24 hours with 20 μM.

ELISA Assay^[3]

Cell Line:

Raw264.7 mouse macrophages pretreated with 5-HT2/5-HT7 receptor antagonist LY215840
Concentration:

20 μM
Incubation Time:

24 h
Result:

Reduced LPS-induced IL-6 production to ~45% of LPS-only levels.
Increased LPS-induced TNFα production to ~180% of LPS-only levels.
Co-treatment with LY215840 (10 nM, 100 nM, 1 μM) further reduced IL-6 levels to below ~20% of LPS-only levels.
Co-treatment with LY215840 (10 nM, 100 nM, 1 μM) reversed TNFα enhancement, reducing levels to ~80%, ~40%, and ~40% of LPS-only levels, respectively (for 100 nM and 1 μM LY215840).

体内実験

Paroxetine (8-32 mg/kg) produces a dose-dependent anti-immobility effect in the mouse forced swim test and also exhibits noradrenergic activity^[1].
Paroxetine exerts no significant dopaminergic, sedative, or ethanol-potentiating effects in healthy rodent models^[1].
Paroxetine produces extremely mild cardiovascular effects in healthy cats, rabbits, and dogs compared with tricyclic antidepressants, and exhibits weak quinidine-like activity only at serotonin reuptake-blocking doses^[1].
Combination of Paroxetine with monoamine oxidase inhibitors (MAOIs) or serotonin precursors induces serotonin syndrome in rats^[1].
Paroxetine modulates the hypothalamic-pituitary-adrenal axis and prolactin-related endocrine activity in healthy rats^[1].
Acute treatment with Paroxetine (5 mg/kg) increases extracellular serotonin levels in the brain of healthy rats^[1].
Paroxetine antagonizes apomorphine-induced hypothermia in rats, indicating that it exhibits noradrenergic activity at high doses^[1].
Combination treatment with Paroxetine (for 3 consecutive weeks) and Pravastatin (HY-B0165) increases the blood glucose level of prediabetic, insulin-resistant mice from 128 mg/dl to 193 mg/dl^[2].
Paroxetine (10 mg/kg, i.p., once a day for 14 days) reduces neurogenic pain in rats both before and after sciatic nerve injury^[5].
Paroxetine (0.3-10 mg/kg, orally, single dose) has anti-anxiety and antidepressant effects in rats, increasing social interaction time^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Sprague-Dawley rats^[6]
Dosage:

0.3, 1, 3, 10 mg/kg; single dose
Administration:

p.o.
Result:

Reduced the synthesis rate of serotonin and increased the social time of rats, but had no effect on motor activity. The motor activity of animals taking the drug for a long time was slightly lower than that of animals taking the drug for a short time.

化学情報

CAS 番号 61869-08-7
性状 Liquid (Density: 1.213±0.06 g/cm³)
分子量 329.37
分子式 C₁₉H₂₀FNO₃
Color Colorless to light yellow
SMILES

FC1=CC=C(C=C1)[C@H]2[C@@H](CNCC2)COC3=CC=C4OCOC4=C3
別名

BRL29060
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Publications (19)

All In Vivo Efficacy StudyCell Proliferation/Viability AssayRT-PCRWBBio/Physico-chemical AssayIFHistological Imaging/Staining2D/3D Cell Culture and Differentiation

Sort by:

Journal Impact Factor

Cell

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. [Abstract]

2021 Apr 15;184(8):2167-2182.e22. PMID: 33811809
Autophagy

Lysosomal damage due to cholesterol accumulation triggers immunogenic cell death. [Abstract]

2025 May;21(5):934-956. PMID: 39663580
NPJ Digit Med

Tandospirone augments cisplatin treatment by lowering cholesterol and managing distress in NSCLC patients. [Abstract]

2025 Nov 17;8(1):663. PMID: 41249389

Paroxetine purchased from MedChemExpress. Usage Cited in: NPJ Digit Med. 2025 Nov 17;8(1):663. [Abstract]

Heat map display of cell viabilities of A549 (Left) and H1299 (Right) cells after incubation with different concentrations of anti-ED compounds (Paroxetine (10–200 μg/mL), et al.) for 48 h. The results showed that paroxetine did not significantly promote tumor cell proliferation; instead, it exerted a mild inhibitory effect on cell growth at higher concentrations.
Cell Rep Med

5-HT reuptake blockade induces pyroptosis in BRAFV600E-mutated melanomas via remodeling histone serotonylation. [Abstract]

2026 Jan 20;7(1):102537. PMID: 41494533

Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]

IC₅₀ of Paroxetine hydrochloride (1-12.5 μM) in the indicated cell lines.

Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]

Colony formation assays in the indicated cells treated with DMSO or gradient doses of Paroxetine hydrochloride (0.5-7.5 μM).

Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]

A375 xenografts were established and treated with vehicle or Paroxetine hydrochloride (25 mg/kg daily intraperitoneally [i.p.]) for 14 days. Tumors in each group were individually recorded every 2 days. n = 8 tumors per group.

Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]

5-HT levels in A375 cells treated with DMSO or the indicated Paroxetine hydrochloride treatment for 24 h.

Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2026 Jan 20;7(1):102537. [Abstract]

A375^DTR xenografts were established and treated with vehicle or PH (25 mg/kg daily i.p. injection) for 15 days. The tumors in each group were individually recorded every 3 days. n = 8 tumors per group.
Cell Rep

LAMP2A-mediated neuronal hyperexcitability by enhancing NKAβ1 degradation underlies depression-induced allodynia. [Abstract]

2025 Apr 2;44(4):115489. PMID: 40178973

Paroxetine purchased from MedChemExpress. Usage Cited in: Cell Rep. 2025 Apr 2;44(4):115489. [Abstract]

Paroxetine (5 mg/kg; i.p.; once daily for 2–3 weeks) alleviated pain and depression-like symptoms in mice subjected to chronic restraint stress (CRS).
J Chem Inf Model

Development of Machine Learning Models and the Discovery of a New Antiviral Compound against Yellow Fever Virus. [Abstract]

2021 Aug 23;61(8):3804-3813. PMID: 34286575
Drug Des Devel Ther

2026 Jan 27;20:1-16.

Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.

CCK-8 assay was performed with different concentrations of Paroxetine (0.0625-10 μM) in BMMs for 1 day and 3 days.

Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.

Assessment of mRNA expression levels of osteoclastogenesis-associated marker genes after administration with Paroxetine (0.0625-2.5 μM) by RT-qPCR, including NFATc1, c-fos, RANK, TRAP, Cathepsin K, and MMP9. he results showed that Paroxetine inhibited the expression of NFATc1, c-fos, RANK, TRAP, Cathepsin K, and MMP9 genes in a concentration-dependent manner.

Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.

Assessment of protein expression levels of NFATc1, c-fos, Cathepsin K and MMP9 after administration with Paroxetine (0.0625-2.5 μM; pretreatment 2 h before stimulation+ 3 d after stimulation) by Western blot. The results demonstrated that, following RANKL stimulation, the protein expression levels of NFATc1, c-fos, CTSK, and MMP9 significantly increased. However, Paroxetine reduced the expression levels of these proteins in osteoclasts in a concentration-dependent manner.

Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.

Representative fluorescence images of P65 nuclear translocation following RANKL stimulation without or with Paroxetine (PA) (pretreatment 6 h). The results showed that RANKL stimulation led to a significant increase in the mean nuclear fluorescence intensity of p65, whereas Paroxetine treatment attenuated this effect.

Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.

Histopathology photographs of femoral samples after HE-stained sections. The results revealed that the trabecular bone in the distal femoral region of mice in the LPS group became sparse and thin. In contrast, Paroxetine (PA, 20 mg/kg; i.p.; once daily for 10 days) effectively alleviated bone loss, as evidenced by the intact and well-ordered arrangement of trabeculae in mice of this group.

Paroxetine purchased from MedChemExpress. Usage Cited in: Drug Des Devel Ther. 2026 Jan 27;20:1-16.

Representative TRAP staining images of RANKL-induced osteoclasts treated with Paroxetine (2.5 μM) on specified days. The results showed that the addition of Paroxetine during the early stage of differentiation (days 1-3) significantly inhibited osteoclast formation. In contrast, when bone marrow-derived macrophages (BMMs) were exposed to Paroxetine from days 3-5 or days 5-7, the number of osteoclasts was also reduced, but the inhibitory effect was less pronounced compared to the early-stage (days 1–3) exposure.
Drug Des Devel Ther

Paroxetine as a Therapeutic Agent in Inflammatory Osteolysis: Mechanistic Insights and Efficacy. [Abstract]

2026 Jan 27:20:561725. PMID: 41868178
Pharmaceuticals (Basel)

Comparative Pharmacological Profiling of Psychotherapeutic Drugs Reveals a Functional Taxonomy Based on Direct Inhibition of Smooth Muscle Excitability. [Abstract]

2026 Apr 21;19(4):645. PMID: 42075900
Int J Mol Sci

Lidocaine Modulates Cytokine Production and Reprograms the Tumor Immune Microenvironment to Enhance Anti-Tumor Immune Responses in Gastric Cancer. [Abstract]

2025 Mar 31;26(7):3236. PMID: 40244064
Front Pharmacol

N-demethylsinomenine metabolite and its prototype sinomenine activate mast cells via MRGPRX2 and aggravate anaphylaxis. [Abstract]

2024 Jul 31:15:1389761. PMID: 39144634
Front Pharmacol

Machine Learning for Discovery of New ADORA Modulators. [Abstract]

2022 Jun 22:13:920643. PMID: 35814244
ACS Omega

Involvement of Integrated Stress Response in Drug-Induced Secondary Dystonia. [Abstract]

2025 Oct 17;10(42):50208-50217. PMID: 41179162
Sci Rep

Paroxetine suppresses 27-hydroxycholesterol-induced responses in THP-1 human monocytic cells by regulating the AKT/mTORC1 pathway. [Abstract]

2025 Oct 21;15(1):36797. PMID: 41120475
Brain Res

Serum miR-221-3p as a new potential biomarker for depressed mood in perioperative patients. [Abstract]

2019 Oct 1:1720:146296. PMID: 31211948

Paroxetine purchased from MedChemExpress. Usage Cited in: Brain Res. 2019 Oct 1:1720:146296. [Abstract]

Protein levels of IFNα and IRF2(B) are detected in HA1800 Cells at 6 h, 12 h and 24 h after paroxetine (10μM) treatment by RT-qPCR and western blot respectively.
Biochem Biophys Res Commun

Screening of potential drugs for the treatment of diabetic kidney disease using single-cell transcriptome sequencing and connectivity map data. [Abstract]

2024 Sep 17:725:150263. PMID: 38905995
J Mol Cell Cardiol Plus

The selective serotonin reuptake inhibitor paroxetine improves right ventricular systolic function in experimental pulmonary hypertension. [Abstract]

2024 Mar 26:8:100072. PMID: 39802918
University of South Carolina

2025.
Patent

US20250127769A1.

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (151.80 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0361 mL

15.1805 mL

30.3610 mL

5 mM

0.6072 mL

3.0361 mL

6.0722 mL

10 mM

0.3036 mL

1.5180 mL

3.0361 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.59 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (287 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Bourin M, et al. Paroxetine: a review[J]. CNS drug reviews, 2001, 7(1): 25-47.

[2]. Nevels RM, et al. Paroxetine-The Antidepressant from Hell? Probably Not, But Caution Required. Psychopharmacology bulletin. 2016 Mar 01;46(1):77-104. [Content Brief]

[3]. Durairaj H, et al. Paroxetine differentially modulates LPS-induced TNFα and IL-6 production in mouse macrophages. International immunopharmacology. 2015 Apr;25(2):485-92. [Content Brief]

[4]. Young-Woo Cho, et al. Paroxetine Induces Apoptosis of Human Breast Cancer MCF-7 Cells through Ca2+-and p38 MAP Kinase-Dependent ROS Generation. Cancers (Basel). 2019 Jan 9;11(1):64. [Content Brief]

[5]. Malek Zarei, et al. Paroxetine attenuates the development and existing pain in a rat model of neurophatic pain. Iran Biomed J. 2014;18(2):94-100. [Content Brief]

[6]. S Lightowler, et al. Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav. 1994 Oct;49(2):281-5. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.0361 mL	15.1805 mL	30.3610 mL	75.9025 mL
	5 mM	0.6072 mL	3.0361 mL	6.0722 mL	15.1805 mL
	10 mM	0.3036 mL	1.5180 mL	3.0361 mL	7.5902 mL
	15 mM	0.2024 mL	1.0120 mL	2.0241 mL	5.0602 mL
	20 mM	0.1518 mL	0.7590 mL	1.5180 mL	3.7951 mL
	25 mM	0.1214 mL	0.6072 mL	1.2144 mL	3.0361 mL
	30 mM	0.1012 mL	0.5060 mL	1.0120 mL	2.5301 mL
	40 mM	0.0759 mL	0.3795 mL	0.7590 mL	1.8976 mL
	50 mM	0.0607 mL	0.3036 mL	0.6072 mL	1.5180 mL
	60 mM	0.0506 mL	0.2530 mL	0.5060 mL	1.2650 mL
	80 mM	0.0380 mL	0.1898 mL	0.3795 mL	0.9488 mL
	100 mM	0.0304 mL	0.1518 mL	0.3036 mL	0.7590 mL

Paroxetine

19 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Paroxetine

Antioxidant Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Mitochondria-Targeted Compound Library

Rare Diseases Drug Library

Antidepressant Compound Library

5-HT Receptor Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

Lactylation Compound Library

Apoptosis Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

MedChemExpress（MCE）の使用を引用している文献 Paroxetine

Cytochrome P450 アイソフォーム固有の製品をすべて表示

5-HT Receptor アイソフォーム固有の製品をすべて表示

NO Synthase アイソフォーム固有の製品をすべて表示

Estrogen Receptor/ERR アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (19)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Paroxetine 関連分類

HY-122272 関連分類